Trospectomycin for Treating Acute Pelvic Inflammatory Disease
Author Information
Author(s): Ashwin Chatwani, Vani Dandalou, Ozgur Harmanli, Paul Nyirjesy
Primary Institution: Temple University School of Medicine
Hypothesis
Is intravenous trospectomycin as effective and safe as cefoxitin plus doxycycline for treating acute pelvic inflammatory disease in hospitalized women?
Conclusion
Trospectomycin may be as effective as the combination of cefoxitin and doxycycline for treating acute pelvic inflammatory disease.
Supporting Evidence
- Trospectomycin had a clinical success rate of 95.6%, while the combination treatment had a success rate of 91.6%.
- Both treatment groups had similar lengths of hospital stay and adverse events.
- Trospectomycin was effective against Chlamydia trachomatis, which cefoxitin is not.
Takeaway
This study looked at a new antibiotic called trospectomycin to see if it works as well as a common combination of two other antibiotics for treating a serious infection in women.
Methodology
A prospective, single-blind study comparing the efficacy and safety of intravenous trospectomycin to cefoxitin plus doxycycline in 39 hospitalized women with acute PID.
Limitations
The study is preliminary and involved a small sample size.
Participant Demographics
Patients were women hospitalized with acute PID, average age around 26 years.
Statistical Information
P-Value
0.63
Statistical Significance
p=0.63
Want to read the original?
Access the complete publication on the publisher's website